Is doxycycline 100 mg daily recommended as an adjunct to HIV pre‑exposure prophylaxis (PrEP) for preventing bacterial STIs, and what are the contraindications and monitoring requirements?

Doxycycline in PrEP: Post-Exposure Prophylaxis, Not Daily Adjunct

Doxycycline is NOT recommended as a daily 100 mg adjunct to HIV PrEP; instead, use doxycycline 200 mg as post-exposure prophylaxis (doxy-PEP) taken within 72 hours after condomless sex for men who have sex with men (MSM) and transgender women at substantial risk for bacterial STIs. 1

Who Should Receive Doxy-PEP

The 2024 CDC guidelines are clear and specific about eligible populations:

Recommended for:

• MSM and transgender women who have had a bacterial STI (syphilis, chlamydia, or gonorrhea) diagnosed in the past 12 months 1
• Can be discussed with MSM and transgender women without recent STI diagnosis but engaging in high-risk sexual activities 1

NOT recommended for (insufficient evidence):

• Cisgender women
• Cisgender heterosexual men
• Transgender men
• Other queer and nonbinary persons 1

This is a critical distinction—the evidence base is limited to specific populations, and extending use beyond these groups lacks supporting data.

Dosing Regimen

The correct dosing is event-based, not daily:

• 200 mg doxycycline (any formulation) taken as soon as possible within 72 hours after oral, vaginal, or anal sex
• Maximum dose: 200 mg every 24 hours (do not exceed this even with multiple sexual encounters) 1
• Prescribe sufficient doses based on anticipated sexual activity until next visit 1

This is fundamentally different from daily prophylaxis—it's a post-exposure strategy, not a continuous regimen.

Contraindications and Precautions

Key contraindications include:

• Known hypersensitivity to tetracyclines
• Pregnancy (tetracyclines cause fetal harm)
• Children under 8 years (causes permanent tooth discoloration) 2

Important drug interactions requiring 2-hour separation:

• Dairy products
• Antacids
• Supplements containing calcium, iron, magnesium, or sodium bicarbonate 1

Notable: No clinically relevant interactions with gender-affirming hormonal therapy 1

Monitoring Requirements

Initial Visit

• Screen for gonorrhea and chlamydia at all anatomic sites of exposure (throat, rectum, urethra/urine)
• Serologic testing for syphilis
• HIV testing per CDC HIV PrEP guidelines if on PrEP; otherwise consider every 3-6 months 1
• Review complete medication list for drug interactions 1

Follow-up Every 3-6 Months

• Screen for gonorrhea and chlamydia at anatomic sites of exposure
• Syphilis serology
• HIV screening per guidelines
• Assess for doxycycline side effects
• Re-assess continued need for doxy-PEP 1

The ongoing need assessment is crucial—this isn't indefinite prophylaxis but should be tailored to changing risk profiles.

Patient Counseling Requirements

Mandatory counseling topics:

Side effects to discuss:

• Photosensitivity (sun sensitivity)
• Esophagitis and esophageal discomfort
• Gastrointestinal intolerance (nausea, vomiting, diarrhea)
• Potential antimicrobial resistance development
• Unknown long-term effects on microbiome 1

Mitigation strategies:

• Take on a full stomach with a full glass of liquid
• Avoid lying down for 1 hour after taking doxycycline to prevent esophagitis 1
• Use sun protection

Critical instructions:

• Take exactly as prescribed, only for intended purpose
• Do not exceed 200 mg per 24 hours
• Take as soon after sex as possible, but no later than 72 hours 1

Evidence Quality and Nuances

The 2024 CDC guidelines 1 represent the most authoritative source, based on randomized controlled trials demonstrating efficacy in reducing syphilis, chlamydia, and to a lesser extent gonorrhea in MSM and transgender women. A 2025 meta-analysis confirmed doxy-PEP reduces first STI incidence (HR 0.538) and specifically Chlamydia trachomatis infection (RR 0.291) 3.

Important limitation: The evidence for daily doxy-PrEP (100 mg daily) is substantially weaker than for event-based doxy-PEP. One study in female sex workers showed promise 4, but this doesn't translate to a general recommendation for daily use as HIV PrEP adjunct.

Antimicrobial resistance concerns: While theoretical concerns exist about promoting resistance, recent microbiome studies show minimal compositional changes over 12 months 5. However, ongoing surveillance is critical, particularly for Neisseria gonorrhoeae resistance 6.

Common Pitfalls to Avoid

1. Don't prescribe daily doxycycline 100 mg as continuous prophylaxis—this is not the evidence-based approach
2. Don't extend to populations without evidence—cisgender women and heterosexual men lack supporting data 1
3. Don't forget the 72-hour window—efficacy depends on timely post-exposure administration
4. Don't skip the comprehensive sexual health approach—doxy-PEP must be part of broader STI prevention including risk reduction counseling, condom provision, and regular screening 1
5. Don't prescribe without establishing monitoring plan—3-6 month follow-up is mandatory, not optional

Implementation Context

Doxy-PEP should be offered through shared decision-making 1, acknowledging both benefits (significant STI reduction) and uncertainties (long-term resistance patterns, microbiome effects). This is particularly relevant given the rising incidence of syphilis, chlamydia, and gonorrhea nationally, which provides the public health rationale for this intervention 1.

The strategy is most appropriate for individuals at substantial ongoing risk who can adhere to event-based dosing and regular monitoring schedules.